Astria Therapeutics to Present at EAACI Congress

Astria Therapeutics, Inc., a biopharmaceutical company listed on NASDAQ as ATXS, is dedicated to creating transformative treatments for allergic and immunological conditions. The company recently announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, scheduled to take place in Valencia, Spain, on June 1, 2024. At this event, Astria Therapeutics will present two significant research posters.

Dr. Marcus Maurer, M.D., a Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present a poster detailing the ALPHA-SOLAR clinical trial. This trial is an extensive, long-term, open-label study focusing on the efficacy of STAR-0215 in treating individuals with Hereditary Angioedema (HAE). The poster, titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)," will be showcased in a session on June 1 at 12:00pm CEST.

Additionally, Nikos Biris, Ph.D., who serves as the Senior Director of Assay Development at Astria Therapeutics, will present a poster on STAR-0310. This poster, titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody," will also be featured in a session on June 1 at 12:00pm CEST. The research focuses on the development and distinctive features of STAR-0310, an innovative monoclonal antibody that acts as an OX40 antagonist.

Astria Therapeutics is committed to delivering groundbreaking therapies to individuals and families impacted by allergic and immunological diseases. The company’s primary program, STAR-0215, is a monoclonal antibody developed to inhibit plasma kallikrein, and it is currently undergoing clinical trials as a treatment for hereditary angioedema. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling. The condition can be life-threatening if it affects the airways, making effective treatments like STAR-0215 critical for patient care.

In addition to STAR-0215, Astria Therapeutics is advancing its second program, STAR-0310. This program involves a monoclonal antibody that functions as an OX40 antagonist, and it is in the preclinical development phase for treating atopic dermatitis, a chronic skin condition that causes severe itching and discomfort.

Astria Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions through innovative therapeutic solutions. The company is positioned at the forefront of biopharmaceutical research, emphasizing the development of therapies that address significant unmet medical needs in the realm of allergic and immunological diseases.

The upcoming presentations at the EAACI Congress reflect Astria Therapeutics' ongoing commitment to scientific excellence and patient care. By sharing their research findings with the broader medical and scientific community, the company hopes to foster collaboration and advance the understanding and treatment of these complex diseases.

Astria Therapeutics continues to focus on its mission to bring life-changing treatments to those affected by allergic and immunological disorders, reaffirming its dedication to innovation and patient health.